Identification of patients with hepatitis c virus infection in persons with background of intravenous drug use: The first community announcementbased study from Iran

International Journal of Preventive Medicine

Volumn 3, Issue 4, 2012, Pages

  Nobari, Reza Fadaei ^a   Meshkati, Marjan ^b   Ataei, Behrooz ^a   Yazdani, Mohammad Reza ^a   Heidari, Kamal ^b   Kassaian, Nazila ^a   Nokhodian, Zary ^a   Shoaei, Parisa ^a   Yaran, Majid ^a   Adibi, Peyman ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Disease Control Unit   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Announcement; Community; Hepatitis c; Intravenous drug using

Indexed keywords

HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; COMMUNITY PROGRAM; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PILOT STUDY; PREVALENCE; PUBLIC HEALTH SERVICE; VOLUNTEER;

EID: 84865246228     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: The first 25 years and counting. Psychosom Med 2008;70:606-11.
2. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: Integrating HIV prevention into Iran's rural primary health care system. AIDS Behav 2008;12(4 Suppl):S7-12.
3. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: A qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006;3:12.
4. United Nations Office on Drugs and Crime. World Drug Report. Vienna: UNODC; 2005.
5. Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992;156:30-5.
6. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:41-6.
7. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005;6:159-65.
8. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997;26(3Suppl 1):2S-10S.
9. Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: Evidence for parenteral transmission inside prison. Rev Saude Publica 2000;34:431-6.
10. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisonersin England and Wales: A national survey. Commun Dis Public Health 2000;3:121-6.
11. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. Shiraz E Med J 2009;10:162-72.
12. Mohammad-Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection andits related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol 2005;11:4085-9.
13. Hosseini Asl K, Avijgan M, Mohamadnejad M. High prevalence of HBV, HCV, and HIV infections in Gypsy population residing in Shahr-E-Kord. Arch Iran Med 2004;7:20-2.
14. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. World J Gastroenterol 2006;12:7025-8.
15. Lavanchy D. Hepatitis C: Public health strategies. J Hepatol 1999;31(Suppl 1):146-51.
16. Zobeiri M, Adibi P, Alavian SM. Intravenous Drug Use and Hepatitis C Virus in Iran. Hepat Mon 2011;11 [In press].
17. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007;18:359-63.
18. Mirahmadizadeh AR, Kadivar MR, Hemmati AR, Javadi A. Infection with HIV and hepatitis C and B viruses among injecting drug users in Shiraz, Southern Iran. International Conference on AIDS 2004;15:16-9.
19. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: Is it a serious problem. Arch Iran Med 2001;4:115-9.
20. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandarabbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis 2009;13:356-8.
21. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iran Med 2003;6:1-4.
22. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 2007;13:250-6.
23. Mahfoud MZ, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J 2010;13:7-96.
24. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis. Public Health 2008;122:990-1003.
25. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug usersin Flanders: Determinants and geographic differences. Epidemiol Infect 2005;133:127-36.
26. Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: Association of genotypes with clinical parameters with sex and drug- related risk behaviors. Eur J Clin Microbiol Infect Dis 2005;24:514-22.